Please click here to view the slides from Dr Norisuke Kawai.
Please click here to view the slides from Dr Dejun Tang
Please click here to hear the audio from Dr Dejun Tang
PSI Scientific Committee Webinar: Drug Development beyond the FDA/EMA – Opportunities and Challenges in Asia Pacific Development Pathways
Registration fee: None
The webinar is free of charge. However, attendees must register on the PSI website in order to obtain the dial-in details and the webinar link.
Clinical drug development has often had a heavy focus on the needs of the FDA and EMEA. This webinar aims to focus on the needs of the China FDA (cFDA) and Japan’s Pharmaceutical and Medical Device Agency (PMDA) providing both insights into the regulatory requirements, real life examples of local development plans and key things to consider when looking to include these countries in multi-regional trials.
Statistical Challengers and Opportunities on Multi-regional Clinical Trials Including Asian Countries
Dr. Dejun Tang (Novartis Pharma; China)
Multi-regional trials are nowadays widely conducted and many multi-regional clinical trials are carried out including Asian countries. However, along with new opportunities, there are many challenges on scientific, operational, and regulatory aspects for conducting such trials. This presentation will discuss both statistical challenges and opportunities on planning and conducting the multi-regional clinical trials which involve Asian countries. Several examples in some clinical trials will be provided for discussion to illustrate the issues and possible solutions.
Evaluation of a Multi-regional Trial for Global Simultaneous Drug Development
Dr. Norisuke Kawai – (Pfizer Japan Inc.)
In recent years, multi-regional trials (MRCTs) are becoming common for drug development in Japan. The primary objective of MRCT is to evaluate efficacy and safety of the study drug in the overall study population. An important secondary objective of MRCT is to evaluate influential ethnic factors on efficacy and safety of the study drug. It includes investigating whether there is heterogeneity across regions. In this presentation we will discuss a framework, that is, a three-layer approach, to evaluate data from a MRCT. In the three-layer approach, how to interpret data in a MRCT is categorized into three layers: Layer 1 to first look at overall study results, Layer 2 to identify factors which influence overall results from scientific and regulatory perspectives, and Layer 3 to evaluate benefit/risk for a specific country/ region according to the requirements of its regulatory authorities. We will also discuss some statistical approaches for exploring regional heterogeneity of the treatment effect.
Points to Consider in Regional Study Design
Dr. Nicole F. Li – (Roche; China)
ICH E5 stated that data developed in one region can be possibly extrapolated to the new region if a bridging study shows evidence that the drug will behave similarly across regions. However, “Similarity” of efficacy across regions is not clearly defined in ICH E5 guideline. There is lack of regulatory guideline on defining “consistency” in bridging study, and no commonly accepted statistical inference in demonstrating “consistency”. Our work provided statistical, regulatory, clinical considerations and guidance on design and analysis of efficacy bridging trials, and explored how the primary objective should be defined, how to select the consistency criteria, and key considerations on sample size.
We do encourage your participation. If you have questions relating to the Asia-Pacific Development webinar, ahead of the webinar, please email them to Sajda.Ghani@covance.com orjennifer.gilbride@grunenthal.com
We will do our best to discuss them at the webinar.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Whatever your current challenge(s) at work, this workshop will explore what's holding you back, and how barriers can be removed in order to progress and achieve.
A PSI Training Course covering the statistical methods for repeated measures and other clustered data. Course will cover: Conditional models for continuous hierarchical data, Conditional models for continuous longitudinal data, Marginal models (GEE) for continuous longitudinal data & Discrete data.
We’re now searching at all levels for Biostatisticians and Statistical Programmers to join our International BARDS Health Technology Assessment team at our London and Zurich hubs.
The Associate Director of Biostatistics is the key client interface for all statistical issues and discussions.
In this role you will consult in the design of complex and innovative studies and clinical trial programs as well as Leading DMC/DSMB processes.
This is an excellent opportunity for someone that loves working directly with clients, contributing as a high-level project lead and key contributor.
Join our growing team and discover your extraordinary potential by working as a Covance by Labcorp Biostatistician 2 within our early phase biostatistics department.
The opportunity to combine an exciting professional career with excellent quality of life in the Cairngorms National Park area of Scotland.
Join our growing team and discover your extraordinary potential by working as a Covance by Labcorp Principal Biostatistician.
As a seasoned Biostatistician, will work primarily on Immunology: GI and Dermatology trials with a focus on Late Phase studies. Some PK Analysis experience highly desired.
As a seasoned Biostatistician, will work primarily in late phase oncology.
As an experienced pharmaceutical statistician, you will support Cytel and a client of our Functional Service Provider (FSP) division.
As a Sr Bios, you will function independently as Lead Statistician on projects and support/project statistician on others.
The Senior Manager Biostatistics will be responsible for leading biostatistics strategy and activities for a compound and/or for individual clinical studies.
As a Sr Mgr, Biostatistics you will manage a team of Statisticians and Programmers within the FSP department, as well as managing project work.
At its core, the role of a Senior Statistician at Veramed is to provide statistical support to the statistics and programming department across a range of projects, clients and therapeutic areas.
As a Senior or Principal Biotatistician, you will hold a combined project leadership and hands-on technical statistics role, working across a range of phases and therapeutic areas.
You will participate in the development of study protocols including participation in study design discussions and sample size calculations, and review CRFs and data review guidelines.
As a Senior or Principal Statistician, you will hold a combined project leadership and hands-on technical statistics role., working across a range of phases and therapeutic areas.
We are looking for passionate and motivated statisticians to work within our Services team to deliver high quality, innovative, analytical services within a clinical setting as our KerusCloud platform moves into the next phase.
Would you like to join a dynamic, growing firm where you can really make an impact, not just on the company but to accelerate drug development and ultimately benefit patients?
Opportunity to join Amgen's centre for design & analysis. We are looking for a talented Statistician to join the Global Biostatistical Science team.
